Urs A Ochsner

Summary

Publications

  1. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
  3. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
  4. pmc Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity
    Louis S Green
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 53:86-94. 2009
  5. pmc Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism
    Daniel G Driscoll
    Replidyne, Inc, Dept Microbiology, 1450 Infinite Dr, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:2247-8. 2007
  6. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008
  7. doi request reprint Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers
    Urs A Ochsner
    SomaLogic, Inc, 2945 Wilderness Place, Boulder, CO 80301, USA
    Diagn Microbiol Infect Dis 76:278-85. 2013
  8. ncbi request reprint Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents
    Urs A Ochsner
    Replidyne, Inc, 1450 Infinite Dr, Louisville, CO 80027, USA
    Expert Opin Investig Drugs 16:573-93. 2007
  9. pmc Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants to Identify Biomarkers of Latent Tuberculosis Infection
    Mary Ann De Groote
    SomaLogic, Inc, Boulder, Colorado, USA
    J Clin Microbiol . 2016
  10. pmc Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents
    John C Rohloff
    SomaLogic, Inc, Boulder, Colorado, USA
    Mol Ther Nucleic Acids 3:e201. 2014

Collaborators

Detail Information

Publications13

  1. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
    ..This novel agent was investigated for its ability to block the production of toxins and spores, and was tested for efficacy in vivo in a hamster model...
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
    ..The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection...
  3. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
    ..In conclusion, we demonstrate by biochemical, physiologic, and genetic mode-of-action studies that REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target...
  4. pmc Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity
    Louis S Green
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 53:86-94. 2009
    ..These observations provide a potential mechanistic explanation for the reduced growth fitness observed with MetRS mutant strains relative to that with wild-type Staphylococcus aureus...
  5. pmc Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism
    Daniel G Driscoll
    Replidyne, Inc, Dept Microbiology, 1450 Infinite Dr, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:2247-8. 2007
    ..Reversion to the wild-type allele and restoration of high-level resistance occurred with high frequency (>10(-6)), indicating the transient nature of MupA polymorphism...
  6. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008
    ..aureus and can be formulated at high concentrations to minimize the development of resistance. A formulation of REP8839 has demonstrated efficacy in a porcine partial thickness wound infection model against mupirocin-resistant S. aureus...
  7. doi request reprint Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers
    Urs A Ochsner
    SomaLogic, Inc, 2945 Wilderness Place, Boulder, CO 80301, USA
    Diagn Microbiol Infect Dis 76:278-85. 2013
    ..SOMAmers detected toxins A, B and binary toxin in culture supernatants from toxigenic C. difficile, including a BI/NAP1 strain and historic strains...
  8. ncbi request reprint Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents
    Urs A Ochsner
    Replidyne, Inc, 1450 Infinite Dr, Louisville, CO 80027, USA
    Expert Opin Investig Drugs 16:573-93. 2007
    ..This review provides an update on the present strategies to develop novel aaRS inhibitors as anti-infective drugs...
  9. pmc Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants to Identify Biomarkers of Latent Tuberculosis Infection
    Mary Ann De Groote
    SomaLogic, Inc, Boulder, Colorado, USA
    J Clin Microbiol . 2016
    ..We found known and novel proteins that warrant further studies to develop improved tests for LTBI, for predicting progression to active disease and for discriminating LTBI from active TB...
  10. pmc Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents
    John C Rohloff
    SomaLogic, Inc, Boulder, Colorado, USA
    Mol Ther Nucleic Acids 3:e201. 2014
    ..Such a large and growing collection of exquisite affinity reagents expands the scope of possible applications in diagnostics and therapeutics. ..
  11. pmc Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors
    Joseph W Guiles
    Replidyne, Inc, Louisville, CO, USA
    Org Med Chem Lett 2:5. 2012
    ..Initial IC50's in aminoacylation/translation (A/T) assays ranged from 3 to14 μM. This series of compounds are variations on a 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ol scaffold (e.g., 4H-pyridopyrimidine)...
  12. pmc Antibacterial activity of REP8839, a new antibiotic for topical use
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 49:4247-52. 2005
    ..aureus highlights the need for a new topical antibiotic with the ability to inhibit high-level mupirocin-resistant strains and other emerging phenotypes, such as vancomycin-resistant and community-acquired methicillin-resistant isolates...
  13. pmc Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment
    Mary A De Groote
    SomaLogic, Inc, Boulder, Colorado, USA
    PLoS ONE 8:e61002. 2013
    ..The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy...